Phase II trial of triple-receptor tyrosine kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas. This is an ASCO Meeting Abstract from the 2013 ASCO Annual Meeting I. This ...
Calcium channel blockers constitute a class of antihypertensive agents that inhibit voltage-dependent calcium influx in vascular smooth muscle and renal cells. In patients with hypertensive kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results